JP2023519853A - レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置 - Google Patents

レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置 Download PDF

Info

Publication number
JP2023519853A
JP2023519853A JP2022558100A JP2022558100A JP2023519853A JP 2023519853 A JP2023519853 A JP 2023519853A JP 2022558100 A JP2022558100 A JP 2022558100A JP 2022558100 A JP2022558100 A JP 2022558100A JP 2023519853 A JP2023519853 A JP 2023519853A
Authority
JP
Japan
Prior art keywords
rtx
composition
pulmonary
use according
inflammatory disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519853A5 (https=
Inventor
アレクシス ナハマ，
ヘンリー ホンジュン ジ，
アービング エイチ． ザッカー，
ハンジュン ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2023519853A publication Critical patent/JP2023519853A/ja
Publication of JP2023519853A5 publication Critical patent/JP2023519853A5/ja
Priority to JP2026000517A priority Critical patent/JP2026042884A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022558100A 2020-03-30 2021-03-12 レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置 Pending JP2023519853A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000517A JP2026042884A (ja) 2020-03-30 2026-01-05 レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002165P 2020-03-30 2020-03-30
US63/002,165 2020-03-30
US202063122858P 2020-12-08 2020-12-08
US63/122,858 2020-12-08
PCT/US2021/022089 WO2021202084A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000517A Division JP2026042884A (ja) 2020-03-30 2026-01-05 レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置

Publications (2)

Publication Number Publication Date
JP2023519853A true JP2023519853A (ja) 2023-05-15
JP2023519853A5 JP2023519853A5 (https=) 2024-03-22

Family

ID=75340289

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558100A Pending JP2023519853A (ja) 2020-03-30 2021-03-12 レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置
JP2026000517A Pending JP2026042884A (ja) 2020-03-30 2026-01-05 レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026000517A Pending JP2026042884A (ja) 2020-03-30 2026-01-05 レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置

Country Status (8)

Country Link
US (1) US20230143545A1 (https=)
EP (1) EP4125871A1 (https=)
JP (2) JP2023519853A (https=)
KR (1) KR20220161423A (https=)
CN (1) CN115666551A (https=)
AU (1) AU2021248861A1 (https=)
CA (1) CA3173611A1 (https=)
WO (1) WO2021202084A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300072A (en) * 2020-08-11 2023-03-01 Sorrento Therapeutics Inc Treatment of pneumonia by nerve ablation
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531085A (ja) * 1998-12-01 2002-09-24 グラクソ グループ リミテッド ヒト・バニロイド受容体およびその使用
JP2017513864A (ja) * 2014-04-14 2017-06-01 フレックス ファーマ， インコーポレイテッド イオンチャネル活性化剤及び使用方法
WO2019049112A1 (en) * 2017-09-11 2019-03-14 Sorrento Therapeutics, Inc. RESINIFERATOXIN FORMULATION
JP2020506207A (ja) * 2017-02-09 2020-02-27 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 末梢動脈疾患の治療のための組成物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531085A (ja) * 1998-12-01 2002-09-24 グラクソ グループ リミテッド ヒト・バニロイド受容体およびその使用
JP2017513864A (ja) * 2014-04-14 2017-06-01 フレックス ファーマ， インコーポレイテッド イオンチャネル活性化剤及び使用方法
JP2020506207A (ja) * 2017-02-09 2020-02-27 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 末梢動脈疾患の治療のための組成物および方法
WO2019049112A1 (en) * 2017-09-11 2019-03-14 Sorrento Therapeutics, Inc. RESINIFERATOXIN FORMULATION

Also Published As

Publication number Publication date
EP4125871A1 (en) 2023-02-08
CN115666551A (zh) 2023-01-31
CA3173611A1 (en) 2021-10-07
US20230143545A1 (en) 2023-05-11
AU2021248861A1 (en) 2022-10-13
WO2021202084A1 (en) 2021-10-07
JP2026042884A (ja) 2026-03-11
KR20220161423A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
JP2026042884A (ja) レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置
Lee Respiratory sensations evoked by activation of bronchopulmonary C-fibers
Rickards Cerebral blood‐flow regulation during hemorrhage
JP2023537515A (ja) 神経切除による肺炎症性疾患の処置
Reynvoet et al. Epidural dextran 40 patch for postdural puncture headache
Taxini et al. Control of the central chemoreflex by A5 noradrenergic neurons in rats
Keegan et al. Pulmonary edema after resection of a fourth ventricle tumor: possible evidence for a medulla-mediated mechanism
US20210322510A1 (en) Oxytocin improves treatment of obstructive sleep apnea
Ali et al. Cardiac rupture during electroconvulsive therapy
Yılmaz Anesthesia management for carotid endarterectomy
Yalcin et al. The effect of centrally administered erythropoietin on cardiovascular and respiratory system of anaesthetized rats
Marcus et al. Sleep and breathing in children: developmental changes in breathing during sleep
Verma Continuous rate infusion anaesthesia with dexmedetomidinemidazolam-ketamine-lignocaine in dexmedetomidine-butorphanolmidazolam-ketamine anaesthetised dogs
KR20140015150A (ko) 급성 악화성 천식의 치료 및 이로부터 고통받는 환자의 입원 가능성의 감소
SPURTHI Comparison of low dose dexmedetomidine and clonidine as adjuvants to bupivacaine in ultrasound guided supraclavicular brachial plexus block
US20240415859A1 (en) Use of isorhoifolin and derivative thereof in promoting nerve repair
Hahka et al. Resiniferatoxin (RTX) ameliorates acute respiratory distress syndrome (ARDS) in a rodent model of lung injury
TAMIL et al. A CLINICAL COMPARISON BETWEEN BUPIVACAINE (PLAIN) AND BUPIVACAINE-MIDAZOLAM IN BRACHIAL PLEXUS BLOCK VIA SUPRACLAVICULAR APPROACH
Chaithali A Study to Assess the Effect of Pretreatment with Intravenous Palonosetron in Preventing Pain on Propofol Injection
Arellano et al. Abadir AR, Humayum SG, Calvello D, Gintautas J. Effects of isoflurane and oxytocin on gravid human uterus in vitro (abstract) S1
Priya A Comparative Study Between Intravenous Dexmedetomidine 0.6 µG/kg Body Weight and Fentanyl 2 µG/kg Body Weight to Attenuate Haemodynamic Response to Laryngoscopy and Endotracheal Intubation in Adult Patients Posted for Elective Surgeries
Al Hashemi Effects of Upper Airway Anaesthesia on the Hyperdynamic Response to Tracheal Intubation
Alemanno Complications of Supraclavicular Techniques
Mahendran A Comparative study on three doses of Esmolol to attenuate the Hemo Dynamic Stress Response during Laryngoscopy and Endo Tracheal Intubation
Katlinge A Comparative Study Between Isobaric Levobupivacaine and Isobaric Levobupivacaine with Fentanyl in Patients Posted for Lower Abdominal and Lower Limb Surgeries Under Spinal Anaesthesia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105